ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00141414
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : January 1, 2007
Sponsor:
Information provided by:
Pfizer

August 30, 2005
September 1, 2005
January 1, 2007
November 1997
Not Provided
Safety
Same as current
Complete list of historical versions of study NCT00141414 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.
To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Epilepsy, Partial
Drug: Pregabalin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
82
Same as current
October 2005
Not Provided

Inclusion Criteria:

  • Must have met the inclusion criteria for preceding double-blind study.
  • Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria:

  • Pregnant or considering becoming pregnant.
  • Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   United States
 
 
NCT00141414
1008-008
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP